Astex Pharmaceuticals, Inc.
4140 Dublin Boulevard
About Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.
• Fiscal strength with significant cash, ongoing revenues and potential milestone payments
• Productive partnerships with top-tier pharmaceutical companies
• Rich product portfolio with multiple drugs in clinical development
• Visionary leadership backed by a world-class management team
We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Our primary areas of focus are oncology and hematology.
We are a publicly traded pharmaceutical company with strong cash reserves and royalty revenues from the sales of our product DACOGEN®. In addition, our partnerships could deliver significant product milestones and future royalties.
277 articles with Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, a member of the Otsuka group of companies, and Otsuka Pharmaceutical, indicated their guadecitabine (SGI-110) missed its co-primary endpoints in acute myeloid leukemia (AML).
Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASTRAL-1 Study of Guadecitabine (SGI-110) in Treatment-Naïve AML Patients Ineligible to Receive Intense Induction Chemotherapy
Astex Pharmaceuticals announce top-line results from the ASTRAL-1 study evaluating the efficacy and safety of guadecitabine (SGI-110) in adults with previously untreated AML who are not eligible for intensive induction chemotherapy.
Astex Continues to Deliver in Oncology as Erdafitinib, a Potential New Treatment for Metastatic Urothelial Cancer, Receives US FDA Breakthrough Therapy Designation
Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its pharmaceutical collaborator, Janssen Pharmaceutica N.V. (Janssen), has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer.
The Award was presented to Dr. Jhoti by BIA Chair, Dr. Jane Osbourn.
Astex Pharma To Showcase Its Next-Generation Hypomethylating Agents Being Developed For Treatment Of AML/MDS At The 2016 Annual Meeting Of American Society of Hematology
Astex Pharma Achieves Milestone On FDA Filing Of New Drug Application (NDA) For LEE011 (Ribociclib) Plus Letrozole As A First-Line Treatment For HR+/HER2- Advanced Breast Cancer
Astex Pharmaceuticals Announces Orphan Drug Designation For Guadecitabine (SGI-110) In The Treatment Of Acute Myeloid Leukemia
Astex Pharmaceuticals Announces Publication Of Key Clinical Data For Guadecitabine (SGI-110) In The Lancet Oncology
Astex Pharmaceuticals Presents Final Results Of Phase 2 Study Of SGI-110 In Treatment Naïve Elderly Acute Myeloid Leukemia At The European Hematology Association Meeting
Astex Pharmaceuticals to Present at American Association for Cancer Research-National Cancer Institute-EORTC